Clinical Trials
454 trialsNCT02316548 2026-05-22
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NRG Oncology
Phase 2 Terminated
NCT03324282 2026-05-22
GCISAVE
University Hospital, Bordeaux
Phase 2 Terminated
NCT01885949 2026-05-20
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT04716725 2026-05-15
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT04030559 2026-05-14
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
University of California, Davis
Phase 2 Terminated
NCT05512377 2026-05-14
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
Phase 2 Terminated
NCT04631744 2026-05-01
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Terminated
NCT06630325 2026-04-28
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT05581589 2026-04-27
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
Phase 2 Terminated
NCT05588609 2026-04-27
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Partner Therapeutics, Inc.
Phase 2 Terminated
NCT04984343 2026-04-23
FORT
Weill Medical College of Cornell University
Phase 2 Terminated
NCT06760702 2026-04-17
TEJAS-2
Aurigene Discovery Technologies Limited
Phase 2 Terminated
NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT04904302 2026-03-20
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03652298 2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2 Terminated
NCT02946996 2026-03-05
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Medical University of South Carolina
Phase 2 Terminated
NCT06114940 2026-03-05
PLUTO
Jinling Hospital, China
Phase 2 Terminated
NCT05676463 2026-03-03
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT04754425 2026-02-06
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05366842 2026-01-30
Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care
Johns Hopkins University
Phase 2 Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT04601857 2025-12-31
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.
Phase 2 Terminated
NCT05067777 2025-12-15
mPROSTATE
University of Utah
Phase 2 Terminated
NCT02772562 2025-12-12
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
Medical University of South Carolina
Phase 2 Terminated
NCT04176497 2025-12-11
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT06818305 2025-12-11
EmFin-Nx
Jinling Hospital, China
Phase 2 Terminated
NCT03274258 2025-12-03
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04779151 2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT04955743 2025-11-24
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT04635059 2025-11-17
BLAST
Medical College of Wisconsin
Phase 2 Terminated
NCT05935748 2025-11-12
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Phase 2 Terminated
NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT03747419 2025-10-31
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04586244 2025-10-30
Optimus
Incyte Corporation
Phase 2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT05846646 2025-10-20
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT01382706 2025-10-09
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
Phase 2 Terminated
NCT04616547 2025-10-03
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04985604 2025-10-02
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 2 Terminated
NCT04887831 2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT04936230 2025-08-17
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04336943 2025-08-11
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
University of Washington
Phase 2 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT03432897 2025-07-08
337
Brown University
Phase 2 Terminated
NCT04102124 2025-06-24
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated